Fluarix Tetra
Fluarix Tetra is a biological therapy with 7 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
1
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
6 of 6 finished
0.0%
0 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.
Influenza Vaccine With Topical Imiquimod in Influenza Vaccine Non-responsive Children
A Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine
Clinical Trials (7)
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.
Influenza Vaccine With Topical Imiquimod in Influenza Vaccine Non-responsive Children
A Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine
Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above
T-cell Diversity Following Intranasal and Intramuscular Vaccines
All 7 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 7